Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036415 | 1.00 | ECE1 (0.41) | ECE1PDCD1LG2CD274ELANECTSD | |
| SCHEMBL20694366 | 0.84 | GNPAT (0.39) | — | |
| SCHEMBL14417629 | 0.81 | ECE1 (0.42) | ECE1PDCD1LG2CD274MMP8 | |
| SCHEMBL13668733 | 0.80 | ECE1 (0.40) | ECE1CTSDBACE1MMP8 | |
| SCHEMBL24475962 | 0.79 | ECE1 (0.44) | ECE1PDCD1LG2CD274CTSDBACE1 | |
| SCHEMBL25602958 | 0.79 | ECE1 (0.44) | ECE1PDCD1LG2CD274CTSDBACE1 | |
| SCHEMBL22695838 | 0.79 | ECE1 (0.44) | ECE1PDCD1LG2CD274CTSDBACE1 | |
| SCHEMBL25561006 | 0.79 | ECE1 (0.46) | ECE1PDCD1LG2CD274MMP8 | |
| SCHEMBL10442189 | 0.78 | ECE1 (0.40) | ECE1 | |
| SCHEMBL12661237 | 0.78 | ECE1 (0.40) | ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271665-B1 | HIGHLY BRIDGED PEPTIDES FROM ACTINOMADURA NAMIBIENSIS | SANOFI SA (FR) | 2012-01-18 | — | — | EP | disclosed |
| US-20110144001-A1 | HIGHLY BRIDGED PEPTIDES FROM ACTINOMADURA NAMIBIENSIS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| US-20110144001-A1 | HIGHLY BRIDGED PEPTIDES FROM ACTINOMADURA NAMIBIENSIS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| WO-2009121483-A1 | HIGHLY BRIDGED PEPTIDES FROM ACTINOMADURA NAMIBIENSIS | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144001-A1 | HIGHLY BRIDGED PEPTIDES FROM ACTINOMADURA NAMIBIENSIS | HM13, VIP, NPBWR1 | ECE1 3759/4885PDCD1LG2 2876/4885CD274 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.